Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Diabete Type 2
Phase NA
Enrollment 230
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

In France, the overall prevalence of diabetes was estimated at 5% of population in 2016, type 2 diabetes (T2DM) corresponding to 90% of cases. However, this figure is greatly underestimated,since it does not take into account people who are untreated or not diagnosed. However,it is estimated that 20 to 30% of adults with diabetes do not are not diagnosed. Conclusions presented during the annual meeting of the european Association for the Study of diabetes (EASD-Berlin) from 2019 suggest that signs precursors of the disease would be present up to 20 years before the diagnosis. The Diagnosis is usually made around 40-50 years. The main factor of risk of T2D is the lifestyle, in particular a diet too rich for a too sedentary daily life. From a medico-economic point of view, chronic pathologies (including diabetes) account for 60% of insurance expenditure illness even though they concern 35% of insured persons, i.e. 20 million patients. The average annual repayment of a type 2 diabetic patient is 4890 euros. This study is part of this context as the starting point a reflection on a different, coordinated management, to know a preventive rather than a curative approach.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Study nurse intervention — Contact everay 4 months with a dedicated study nurse

Primary Outcomes

  • FINDRISC score (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-03-20
Completion: 2028-04-01
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
Collaborators: European Clinical Trial Experts Network
Contact Information
Study Contact:
JF OUDET
068346567
jf.oudet@ecten.eu
MH BArba
0664888704
MH.Barba@ecten.eu
Aurélie LIETAER, DR
Clinique Aguiléra
Interventions
  • Behavioral: Study nurse intervention — Contact everay 4 months with a dedicated study nurse
Study Locations (1 sites)
Clinique Aguiléra, Biarritz, Aquitaine 64200 France
Eligibility Criteria
Inclusion Criteria: * Patient, male or female, over the age of 18 * Patient with a FINDRISC score ≥10 points * Beneficiary of a French health insurance system * Patient having been informed and having given their consent free, enlightened and written Exclusion Criteria: * Patient over 75 years old * Patient already diagnosed with type 2 diabetes * Patient whose physical and/or psychological health is severely impaired, which according to the investigator may affect the compliance of the study participant. * Patient participating in another research * Patient in period of exclusion from another research always in progress at the time of inclusion. * Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by court order or administration. * Pregnant, breastfeeding or parturient women. * Patient hospitalized without consent
Conditions Diabetes Mellitus, Type 2, Impaired Gluc...
Phase NA
Enrollment 700
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dapagliflozin — 10mg/day
  • Drug: Saxagliptin — 5mg/day
  • Drug: Pioglitazone — the dose will increase from 15 mg/day to 30 mg/day at month two
  • Drug: Metformin — starting at 1000 mg/day and increased to 2000 mg/day at month 2.

Primary Outcomes

  • Beta cell function (24 months after treatment phase begins)
  • Insulin sensitivity (24 months after treatment phase begins)
  • Glucose tolerance status (24 months after treatment phase begins)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2014-01-01
Completion: 2027-07
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 700 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center at San Antonio
Collaborators: American Diabetes Association, AstraZeneca, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Ralph A DeFronzo, MD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center at San Antonio
Contact Information
Study Contact:
Ralph A DeFronzo, MD
210-567-6691
defronzo@uthscsa.edu
Monica Palomo, BS
210-567-6710
palomom@uthscsa.edu
Ralph A DeFronzo, MD
210-567-6691
defronzo@uthscsa.edu
The University of Texas Health Science Center at San Antonio
Interventions
  • Drug: Dapagliflozin — 10mg/day
  • Drug: Saxagliptin — 5mg/day
  • Drug: Pioglitazone — the dose will increase from 15 mg/day to 30 mg/day at month two
  • Drug: Metformin — starting at 1000 mg/day and increased to 2000 mg/day at month 2.
Study Locations (1 sites)
The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229 United States
Eligibility Criteria
Inclusion Criteria: * NGT subjects will serve as controls and will be matched in age, gender, ethnicity, and BMI to IGT and IFG subjects 1. Male or female subjects between the ages of 18 and 65 years of age, inclusive, at Screening. 2. FPG \< 100 mg/dl and 2-h PG \< 140 mg/dl 3. BMI = 24-40 kg/m2; 4. Stable body weight (±4lbs) over the preceding 3 months 5. Subjects with no evidence of major organ system disease as determined by physical exam, history, and screening laboratory data 6. Females of childbearing potential with a negative pregnancy test at Screening and Treatment visits, using one of the following forms of contraception for the duration of participation in the study (i.e., until Follow-up 7-14 days post last dose): * Oral contraceptive * Injectable progesterone * Subdermal implant * Spermicidal foam/gel/film/cream/suppository * Diaphragm with spermicide * Copper or hormonal containing IUD * Sterile male partner vasectomized \> 6 month pre-dosing. 7. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. 8. Subjects must be willing and able to comply with scheduled visits, treatment, laboratory tests and study procedures. Exclusion Criteria: 1. Recent (i.e., within three (3) months prior to Screening) evidence or medical history of unstable concurrent disease such as: documented evidence or history of clinically significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, immunological, or clinically significant neurological disease. 2. Subjects with a family history of diabetes in a first degree relative 3. BMI of less than 24 or greater than 40 kg/m2 4. Unstable body weight (change of greater than ±4lbs over the preceding 3 months 5. Subjects participating in an excessively heavy exercise program 6. Subject with a feeding/sleeping schedule different from a daytime feeding/night time sleeping schedule 7. Subjects taking medications known to alter glucose metabolism (with the exception of metformin and/or pioglitazone) or which effect brain neurosynaptic function are excluded. 8. Subjects with evidence of major organ system disease as determined by physical exam, history, and screening laboratory data 9. Pregnant subjects or subjects unwilling to use birth control during their study enrollment 10. Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to Screening. 11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study 12. Subjects with hematuria will be excluded. 13. Subjects with evidence or prior history of heart failure will be excluded 14. Subjects with family history of pancreatic, bladder, and breast cancer will be excluded. 15. Subjects with history of pancreatitis will be excluded. 16. Subjects with eGFR \< 60 ±5 ml/min.1.73m2 will be excluded. 17. Subjects with elevated serum creatinine (\>1.5 mg/dl males/1.4 mg/dl females) will be excluded. 18. Subjects with a history of orthostatic hypotension (\>15/10 mmHg) will be excluded. 19. Subjects with liver enzymes (ALT, AST) \>3-fold above upper normal limit will be excluded. 20. Subjects with a history of hypersensitivity to pioglitazone, dapagliflozin, or Saxagliptin will be excluded.

Driving with Neuropathy

NCT06739135
Recruiting
Conditions Diabetic Polyneuropathy, Diabetes Mellit...
Phase NA
Enrollment 115
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is a proof-of-concept randomised controlled trial (RCT). The goal of the study is to investigate the effectiveness of a feedback intervention to improve use of the accelerator pedal in patients driving with diabetes and peripheral neuropathy (DPN). The main (primary) question it aims to answer is: What is the effect of a visual feedback intervention (over 6 sessions a month apart), compared to no feedback, on accelerator pedal use by drivers with diabetic peripheral neuropathy? Our working hypothesis is that the visual feedback intervention will reduce the % of drive time with the accelerator pedal pushed down further than 9 degrees (about halfway down), the point at which the visual feedback (a warning signal) is triggered. Secondary research questions are: 1. What is the effect of the feedback intervention on drivers with diabetic peripheral neuropathy at the first visit, and at the third visit? When does the biggest improvement happen? Our working hypothesis is that the visual feedback intervention will reduce the % of drive time spent driving with the accelerator pedal pushed down further than 9 degrees, the point at which the feedback is triggered, in the first visit (ie with the first exposure to feedback) and by additional amounts in subsequent visits ie there will be an immediate benefit, and additional benefits that accrue gradually with repetition over the 6 monthly visits. 2. What is the effect of the feedback intervention on a second variable, % of drive time with the vehicle 'out of control'. Out of control is defined as extreme use of the steering wheel, large and rapid movements that reach the full range of motion of the steering wheel or large swings back and forth together with excursion out of lane which the driver fails to prevent. Our working hypothesis is that the visual feedback intervention will reduce the % of drive time with the vehicle out of control. Researchers will compare the group of drivers with neuropathy who receive the intervention with a control group who do not. In addition, a group of drivers who have diabetes but no diagnosed neuropathy will be studied. This is to seek confirmatory evidence (previously seen in a small sample in a previous study) that most drivers who have no diagnosed neuropathy do not push the accelerator pedal down more than 9 degrees and so do not need to improve their use of the accelerator pedal. Participants will have their driving assessed in a driving simulator. Participants with DPN who push the accelerator pedal down more than 9 degrees will then be randomly allocated to the intervention group or control group. Only drivers in the intervention group will go on to experience the visual feedback intervention (in 6 sessions a month apart). Drivers in the control group will have their driving assessed at their first visit, and then at two later visits timed to coincide with the 3rd and 6th visit by drivers in the intervention group. This is the minimum necessary to…

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Visual feedback training — Visual feedback training to modify use of the accelerator pedal when driving in a driving simulator, to reduce the % of time driving with the pedal pushed down more than 9 degrees

Primary Outcomes

  • Percent of drive time with the accelerator pedal pushed down further than 9 degrees at the end of the intervention (visit 6) (The intervention arm of the study has 6 visits that are spaced 1 month apart, with visit 1 being the baseline/randomisation visit. Thus, visit 6 happens at 5 months post-baseline/randomisation.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-25
Completion: 2026-07
Eligibility
Age: 25 Years – 69 Years
Sex: ALL
Volunteers: false
Enrollment: 115 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Manchester Metropolitan University
Principal Investigators:
  • Dilwyn Marple-Horvat, DPhil (PRINCIPAL_INVESTIGATOR) - Manchester Metropolitan University
Contact Information
Study Contact:
Maaike Esselaar, PhD
+44 787 310 9658
m.esselaar@mmu.ac.uk
Dilwyn Marple-Horvat, DPhil
+44 782 444 7605
d.e.marple-horvat@mmu.ac.uk
Maaike Esselaar, PhD
+44 787 310 9658
m.esselaar@mmu.ac.uk
Manchester Metropolitan University
Interventions
  • Behavioral: Visual feedback training — Visual feedback training to modify use of the accelerator pedal when driving in a driving simulator, to reduce the % of time driving with the pedal pushed down more than 9 degrees
Study Locations (1 sites)
Manchester Metropolitan University, Manchester, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Able to understand English and all of the study requirements, including ability to provide informed consent * Current full UK driving licence held, and for a minimum of 5 years (experienced drivers) * Drives a car at least once per week on average (current drivers) * Diagnosed with type 2 diabetes and diabetic peripheral neuropathy * Diagnosed with type 2 diabetes only (no diagnosed diabetic peripheral neuropathy) Exclusion Criteria: * Active foot ulcer on either foot * Lower limb amputation involving more than two toes on the right foot * Dementia * Current participation in another research study that would compromise safety, or scientific integrity of either study (for example, a pharmaceutical trial that may affect ability to drive safely).
Conditions Type 2 Diabetes
Phase PHASE3
Enrollment 360
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This multicenter, randomized, double-Blind, parallel-group, placebo-controlled phase III trial is to evaluate the efficacy and safety of UBT251 Injection in patients with Type 2 Diabetes Mellitus with inadequate glycemic control on diet and exercise alone

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: UBT251 Injection 2.0 mg — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection 4.0 mg — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection 6.0 mg — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection Placebo 2.0 mg — UBT251 Injection placebo subcutaneously once weekly
  • Drug: UBT251 Injection Placebo 4.0 mg — UBT251 Injection placebo subcutaneously once weekly
  • Drug: UBT251 Injection Placebo 6.0 mg — UBT251 Injection placebo subcutaneously once weekly

Primary Outcomes

  • HbA1c (Week 40)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-09-07
Completion: 2027-10-22
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Contact Information
Study Contact:
Haiyan Zhang
+86 18998165570
zhanghy@tul.com.cn
Zhiguang Zhou
0731 8529 5999
The Second Xiangya Hospital of Central South University
Interventions
  • Drug: UBT251 Injection 2.0 mg — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection 4.0 mg — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection 6.0 mg — UBT251 Injection subcutaneously once weekly
  • Drug: UBT251 Injection Placebo 2.0 mg — UBT251 Injection placebo subcutaneously once weekly
  • Drug: UBT251 Injection Placebo 4.0 mg — UBT251 Injection placebo subcutaneously once weekly
Study Locations (1 sites)
The Second Xiangya Hospital of Central South University, Changsha, Hunan China
Eligibility Criteria
Inclusion Criteria: 1. Aged 18-75 years (inclusive) at the time of signing the informed consent form (ICF), regardless of gender; 2. Diagnosed with type 2 diabetes mellitus (T2DM) for at least 3 months in accordance with the 2019 World Health Organization (WHO) criteria; 3. Managed solely through diet and exercise intervention (without the use of any glucose-lowering medications) for at least 3 months prior to screening; 4. Glycated hemoglobin (HbA1c) level ≥7.5% and ≤10.5% at screening; 5. Body mass index (BMI) ≥23.0 kg/m² at screening, and stable body weight (change \<5%, which may be based on the participant's self-report) within 3 months prior to screening; 6. Trial participants (including their partners) have no plan for pregnancy from screening to 6 months after trial completion, and are willing to comply with the contraceptive measures specified in the trial, and have no plan for sperm or egg donation within 6 months after trial completion; 7. Have been fully informed about this study and voluntarily sign a written informed consent form. Exclusion Criteria: 1. Known history of hypersensitivity to this study drug, its drug product excipients, or other similar active drugs; 2. History of medication use within 3 months prior to screening that meets any of the following conditions: 1\) Use of any glucose-lowering medications, including glucagon-like peptide-1 (GLP-1) analogues, oral antidiabetic drugs (OADs) (including but not limited to metformin, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, glinides, sodium-glucose cotransporter 2 (SGLT-2) inhibitors), insulin (except for short-term use ≤14 days for acute conditions, such as perioperative or inpatient use), traditional Chinese medicines, or health supplements with glucose-lowering effects; 2) Use of medications that may affect glucose metabolism, such as systemic glucocorticoids, growth hormone, etc. (except for cumulative use \<7 days with the last dose administered more than 7 half-lives prior to the first day of screening); 3) Use of weight-loss medications (including but not limited to orlistat, liraglutide, or other similar prescription or over-the-counter medications for weight loss); 3.History or evidence of any of the following diseases: 1. Diagnosis of other types of diabetes: such as type 1 diabetes mellitus (T1DM), other specific types of diabetes (e.g., genetic defects in beta-cell function, genetic defects in insulin action, diseases of the exocrine pancreas, etc.); 2. History of acute or chronic pancreatitis, or pancreatic surgery; 3. History of symptomatic gallbladder disease within 1 year before screening (excluding trial participants who have undergone cholecystectomy \[completed at least 3 months before screening\] without long-term complications), or abdominal ultrasound at screening indicating large gallstones (diameter ≥2 cm), gallbladder polyps (diameter ≥1 cm), or other gallbladder lesions that the study physician determines may affect trial participant safety; 4. Personal or family history (within first-degree relatives, i.e., parents, children, or siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2); 5. History of hematological disorders that may affect HbA1c test results or increase the risk to trial participants (e.g., aplastic anemia, myelodysplastic syndromes, etc.), or any diseases causing hemolysis or erythrocyte instability (e.g., sickle cell disease, thalassemia, etc.); 6. History of moderate to severe depression or severe psychiatric disorders (including but not limited to suicidal ideation or attempt, schizophrenia, bipolar disorder, etc.); 7. History of clinically significant cardiovascular or cerebrovascular disease within 6 months before screening 8. Severe retinal or macular disease (including but not limited to proliferative retinopathy, macular edema, retinal detachment, etc.) at screening or in the past, requiring urgent treatment as determined by the study physician; 9. Severe hypoglycemia (hypoglycemia accompanied by severe cognitive impairment requiring assistance from others to recover) or recurrent symptomatic hypoglycemia (≥2 episodes in 6 months) within 6 months prior to screening; 10. History of acute metabolic complications of diabetes (including but not limited to diabetic ketoacidosis \[DKA\], hyperosmolar hyperglycemic state \[HHS\] requiring hospitalization, hyperosmolar coma, lactic acidosis, etc.) or diabetic foot within 6 months prior to screening; 11. History of malignancy; 4.Blood loss ≥400 mL (including trauma, blood draw, blood donation) within 3 months before screening, or receipt of blood or blood component transfusion; 5.Lactating women or pregnant women;
Conditions New-onset Type 2 Diabetes
Phase PHASE4
Enrollment 268
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This multicenter, randomized controlled trial aims to evaluate the efficacy and safety of Henagliflozin-Metformin Sustained-Release Tablets (I) versus Metformin Tablets in newly diagnosed type 2 diabetes mellitus (T2DM). A total of 268 participants will be randomized (1:1) into two groups: the experimental group receiving Henagliflozin-Metformin Sustained-Release Tablets (I) (5mg/500mg, once daily) with lifestyle intervention, and the control group receiving Metformin Tablets (500mg, twice daily) with lifestyle intervention. The primary outcome is the change in glycated hemoglobin (HbA1c) from baseline at 24 weeks. Secondary outcomes include changes in fasting/postprandial blood glucose, body weight, metabolic parameters, diabetes remission rate, and safety assessments. This trial will provide evidence for early combination therapy in newly diagnosed T2DM patients.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ) — henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ) (5mg/500mg, once a day, two tablets each time) plus lifestyle intervention
  • Drug: Metformin — Metformin (500mg, twice a day) plus lifestyle intervention

Primary Outcomes

  • Glycosylated Hemoglobin, Type A1C(HbA1C) (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-04-11
Completion: 2026-12-30
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 268 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang Provincial People's Hospital
Collaborators: Shandong Suncadia Medicine Co., Ltd.
Contact Information
Study Contact:
Xiaohong Wu
+86-13815870351
drxhwu@163.com
Fei Cao
+86-17805050859
caofei1616@163.com
Zhejiang Provincial People's Hospital
Interventions
  • Drug: henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ) — henagliflozin proline and metformin hydrochloride extended-release tablets (Ⅰ) (5mg/500mg, once a day, two tablets each time) plus lifestyle intervention
  • Drug: Metformin — Metformin (500mg, twice a day) plus lifestyle intervention
Study Locations (1 sites)
Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 75 years old. * Diagnosed with type 2 diabetes according to WHO diagnostic criteria, with HbA1c between 7% and 9% at this examination, fasting venous blood glucose ≤ 11.1 mmol/L, and BMI ≥ 18.5 kg/m2; known disease duration ≤ 24 months. * Voluntary participation in this study and signing of the informed consent form. If the subject is unable to read the informed consent form (e.g., illiterate subjects), a witness must be present to observe the informed consent process and sign the informed consent form on their behalf. * No previous use of hypoglycemic drugs. Exclusion Criteria: * Type 1 diabetes. * Participants who have participated in other clinical trials of diabetes treatment drugs before the start of this study. * Those who have experienced diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar non-ketotic coma within the past six months and required hospitalization. * Those who have experienced decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, undergone cardiac surgery or vascular reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) within the past six months. * Those taking glucocorticoid drugs (excluding topical or inhaled medications). * Those with a life expectancy of less than one year due to malignant tumors, active tuberculosis, or acute infections. * Those with clinically significant urinary tract or genital infections, or a history of recurrent urinary tract or genital infections. * Those with a history of hypertension whose blood pressure has not been effectively controlled despite antihypertensive drug treatment: systolic blood pressure (SBP) \> 160 mmHg and/or diastolic blood pressure (DBP) \> 100 mmHg. * Those with liver and kidney function indicators meeting the following criteria: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 3.0×ULN; estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73 m² (calculated according to the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula). * Those allergic to the investigational drug or its components. * Pregnant or lactating women and those with the intention to conceive within three months of the last dose. * Other patients deemed unsuitable for participation in this clinical trial by the investigator.
Conditions Type 2 Diabetes Mellitus, Chronic Kidney...
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Research Objectives To evaluate the impact of finerenone on renal function, diabetic complications, and safety in patients with Type 2 diabetes and chronic kidney disease. Study Design Type: Prospective, single-arm, multicenter clinical trial. Sample Size: 300 patients. Intervention: Finerenone added to existing treatment regimen (10-20 mg once daily, dose adjusted based on eGFR), for 48 weeks. Data Collection Time Points: Baseline, 4 weeks, 12 weeks, 24 weeks, 36 weeks, and 48 weeks. Primary Endpoint: Change in urine albumin-to-creatinine ratio (UACR). Secondary Endpoints: Changes in eGFR, 24-hour urine protein, serum uric acid, retinopathy markers, pulse wave velocity (PWV), ankle-brachial index (ABI), etc. Safety Endpoints: Changes in serum potassium, sodium, and blood pressure.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Drug: Finerenone — Treatment will continue for 48 weeks.

Primary Outcomes

  • Change in Urine Albumin-to-Creatinine Ratio (UACR) (Baseline to Week 48)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-17
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital of Soochow University
Principal Investigators:
  • Xie Ying, Ph.D. (PRINCIPAL_INVESTIGATOR) - Second Affiliated Hospital of Suzhou University
Contact Information
Study Contact:
Xie Ying, Ph.D.
13962187062
13013883877@126.com
Interventions
  • Drug: Finerenone — Treatment will continue for 48 weeks.
Study Locations (1 sites)
The Second Affiliated Hospital of Suzhou University, Suzhou, Jiangsu China
Eligibility Criteria
Inclusion Criteria: * Diagnosed with Type 2 diabetes according to the 1999 WHO criteria * Aged ≥18 years * UACR ≥30 mg/g and eGFR ≥30 ml/min/1.73 m² sustained for over 3 months * Stable ARB/ACEI treatment for ≥4 weeks prior to enrollment * Willing to sign a written informed consent and comply with the study protocol Exclusion Criteria: * Chronic kidney disease diagnosed before Type 2 diabetes * Serum potassium \>4.8 mmol/L * Ineffective blood pressure control at screening (systolic BP ≥160 mmHg and/or diastolic BP ≥100 mmHg, average of three measurements in the supine position) * HbA1c \>9% * Acute urinary tract infection or conditions affecting urine tests * Primary or secondary adrenal insufficiency * Use of mineralocorticoid receptor antagonists * Use of medications with clear effects on urine protein and eGFR within 4 weeks (except kininogenase) * Use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin, nefazodone, carbamazepine) * ALT or AST \>2.5 × ULN, total bilirubin (TBIL) \>2 × ULN * Use of systemic glucocorticoids for more than 7 days within 12 weeks prior to screening, or use of systemic glucocorticoids (intravenous/oral or intra - articular) or need for systemic immunosuppressive treatment within the past 14 days * Any organ system cancer within the past 5 years, whether treated or untreated * Known pregnancy (positive pregnancy test), breastfeeding, recent plans for conception, or not using adequate contraception * Participation in other interventional clinical trials within 3 months prior to screening
Conditions Type 2 Diabetes, Atherosclerosis
Phase PHASE4
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Diabetes is an increasing cause of atherosclerotic and cardiovascular illnesses in South Korea. The clinical application of ultrasound for measuring carotid intima-media thickness, which helps in early detection and surveillance of atherosclerosis, is advancing. Due to lifestyle changes and an aging population, Koreans, especially diabetics, are developing more vascular diseases and are at higher risk for peripheral vascular disorders. Diabetics with lower limb peripheral artery disease require effective therapy to avoid major complications and a reduced quality of life. Although licensed for symptom control, Clopidogrel and Cilostazol have not yet been established for primary prevention of cardiovascular risks. These medications will be evaluated for their potential as primary preventive agents against cardiovascular disease in type 2 diabetes patients. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and to evaluate their influence on hemorheological changes in individuals with Type 2 diabetes. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and evaluating their influence on alterations in blood flow among individuals with Type 2 diabetes.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Clopidogrel — Clopidogrel 75mg once daily
  • Drug: Cilostazol — Cilostazol 200mg per day

Primary Outcomes

  • Changes of carotid intima-media thickness (52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-04-16
Completion: 2027-01-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Bundang Hospital
Collaborators: Samjin Pharmaceutical Co., Ltd.
Principal Investigators:
  • Soo Lim, MD. Ph.D. (PRINCIPAL_INVESTIGATOR) - Seoul National University Bundang Hospital
Contact Information
Study Contact:
Soo Lim, MD. Ph.D.
+82317877035
limsoo@snu.ac.kr
Minji Sohn, Ph.D.
+82317878443
rainbowmjs@naver.com
Soo Lim
+82317877035
limsoo@snu.ac.kr
Seoul National University Bundang Hospital
Interventions
  • Drug: Clopidogrel — Clopidogrel 75mg once daily
  • Drug: Cilostazol — Cilostazol 200mg per day
Study Locations (1 sites)
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do 13620 South Korea
Eligibility Criteria
Inclusion Criteria: * Adults with diabetes aged 19 and older * Individuals with a carotid ultrasound cIMT (carotid intima-media thickness) of 1.0mm or more * Those who have not changed their combination therapy medications (including oral hypoglycemics, antihypertensives, and lipid-lowering drugs) in the last three months * Individuals with an HbA1c level of 10% or less * Those who have voluntarily signed the written consent form and agreed to participate in the study Exclusion Criteria: * Individuals currently using antithrombotic or anticoagulant medications other than aspirin * Individuals with bleeding or conditions that may increase the risk of bleeding, such as: * Hemophilia, capillary fragility, intracranial hemorrhage, upper gastrointestinal bleeding, urinary bleeding, hemoptysis, vitreous hemorrhage, etc * Active peptic ulcer, hemorrhagic stroke within the last 6 months, surgical operations within the last 3 months, proliferative diabetic retinopathy, uncontrolled hypertension * Patients who have had cerebrovascular or cardiovascular complications within the past 6 months (including stroke, transient ischemic attacks, myocardial infarction, unstable angina, coronary artery bypass graft, or percutaneous coronary intervention) * Patients with severe renal or hepatic diseases * Patients with congestive heart failure * Individuals with a history of hypersensitivity to the drug or its components * Pregnant women or women who may be pregnant * Women who are breastfeeding or plan to breastfeed during the study
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase PHASE1
Enrollment 53
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This study is a single-center, randomized, double-blind, placebo- and active-controlled, parallel-group, single-ascending dose (SAD) design. Insulin degludec and insulin icodec injection serves as the active control and is administered in an open-label manner. The study will be conducted across 6 cohorts, comprising 4 dose-escalation cohorts of UBT38006 (1, 3, 6, and 12 nmol/kg) , 1 active control cohort of insulin degludec (0.4 U/kg \[2.4 nmol/kg\]) and 1 active control cohort of insulin icodec (1.25 U/kg \[7.5 nmol/kg\]). The safety and tolerability (including local tolerability) as well as the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single subcutaneous doses of UBT38006 injection will be evaluated in healthy adult male participants. In Cohort 1 (1 nmol/kg), participants will be randomized in a 4:1 ratio to receive UBT38006 injection or placebo. In Cohorts 2-4 (3, 6, and 12 nmol/kg), participants will be randomized in an 8:2 ratio to receive the corresponding dose of UBT38006 injection or placebo. Participants in Cohort 5 (insulin degludec active control) will receive 0.4 U/kg (2.4 nmol/kg) insulin degludec injection. Participants in the insulin icodec cohort received a subcutaneous injection of insulin icodec at a dose of 1.25 U/kg(7.5 nmol/kg). Cohorts 1-4 will follow a double-blind design, while Cohort 5 and insulin icodec cohort will be open-label.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: UBT38006 — Ascending single doses - 4 dose levels
  • Drug: Placebo — Ascending single doses - 4 dose levels
  • Drug: Insulin Degludec Injection — single subcutaneous injection
  • Drug: Insulin Icodec Injection — single subcutaneous injection

Primary Outcomes

  • incidence of adverse events (AEs), adverse drug reactions (ADRs), serious adverse events (SAEs), etc,.. (Baseline to Day43)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-17
Completion: 2026-10-25
Eligibility
Age: 18 Years – 45 Years
Sex: MALE
Volunteers: true
Enrollment: 53 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
Contact Information
Study Contact:
Yu Huang
+86 15940441913
huangyu_0518@tul.com.cn
Hu Wei Chief Pharmacist
+86 13856086475
huwei@ahmu.edu.com
The Second Hospital of Anhui Medical University
Interventions
  • Drug: UBT38006 — Ascending single doses - 4 dose levels
  • Drug: Placebo — Ascending single doses - 4 dose levels
  • Drug: Insulin Degludec Injection — single subcutaneous injection
  • Drug: Insulin Icodec Injection — single subcutaneous injection
Study Locations (1 sites)
The Second Hospital of Anhui Medical University, Hefei, Anhui China
Eligibility Criteria
Inclusion Criteria: * Aged 18-45 years (inclusive) at the time of informed consent form (ICF) signing; * Sex: Male; * Body weight ≥50.0 kg and body mass index (BMI) between 19.0-24.0 kg/m² (BMI = weight \[kg\] / height² \[m²\]), inclusive, at Screening; * Fasting plasma glucose (FPG) between 3.9-6.1 mmol/L (exclusive of boundary values) at Screening; 2-hour plasma glucose \<7.8 mmol/L on oral glucose tolerance test (OGTT) at Screening; insulin release test (IRT) results normal, or abnormal but judged by the Investigator as not clinically significant (NCS)at Screening; glycated hemoglobin (HbA1c) ≤6.0% at Screening; * The subject (including his partner) is willing to use adequate and effective contraception voluntarily from Screening through 3 months after administration of the investigational medicinal product (IMP) (see Appendix 2 for details), and has no plan to donate sperm within 3 months after IMP administration; * The subject is able to communicate well with the Investigator, has adequate understanding of this study, participates voluntarily, understands and complies with all study requirements, and provides written informed consent. Exclusion Criteria: * History of severe hypersensitivity (e.g., allergy to three or more allergens, allergic asthma involving the lower respiratory tract, or allergy requiring systemic corticosteroid therapy) or known hypersensitivity to any component of the investigational medicinal product; * History of severe or currently clinically significant disease/condition (including but not limited to diseases of the nervous, cardiovascular, respiratory, hematologic and lymphatic, immune, renal, hepatic, gastrointestinal, metabolic, and skeletal systems, history of malignancy, or neurological or psychiatric disease/condition); * History of orthostatic hypotension, syncope, or amaurosis, or first-degree relative with history of diabetes mellitus; * Laboratory abnormalities (hematology, blood chemistry, coagulation function, thyroid function, urinalysis, stool routine, etc.) at Screening that are judged by the Investigator as clinically significant; * Positive insulin autoantibody (IAA) at Screening; * Positive hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody, or Treponema pallidum antibody at Screening; * History of drug abuse, or positive urine drug screen prior to randomization; * Clinically significant abnormalities on physical examination, electrocardiogram (ECG), or vital signs (body temperature, pulse, blood pressure); * Use of insulin-containing agents within 3 months prior to dosing, or use of any other medication (including traditional Chinese medicine, over-the-counter drugs, etc.) within 30 days prior to dosing; * Vaccination with any vaccine within 1 month prior to dosing; * History of surgery within 3 months prior to dosing, or planned surgery during the entire study period; * History of blood loss or blood donation exceeding 200 mL within 3 months prior to dosing (calculated from the day before dosing); * Hemoglobin below the lower limit of normal (LLN); * Participation in other interventional clinical trials within 3 months prior to dosing (except for subjects who only underwent screening but were not enrolled, or were enrolled but did not receive treatment);
Conditions Obesity, Overweight
Phase PHASE3
Enrollment 351
Locations 49 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adult participants living with obesity or overweight with or without T2DM.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Elecoglipron — Elecoglipron film coated tablet once daily
  • Drug: Placebo — Placebo matching elecoglipron film-coated tablet once daily

Primary Outcomes

  • Percent change from baseline to Week 52 in body weight (Week 52)
  • Participants achieving at least 5% body weight loss at Week 52 (Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-08-21
Completion: 2028-04-13
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 351 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: Elecoglipron — Elecoglipron film coated tablet once daily
  • Drug: Placebo — Placebo matching elecoglipron film-coated tablet once daily
Study Locations (49 sites)
Research Site, Baotou, 014040 China
Research Site, Beijing, 100044 China
Research Site, Beijing, 100050 China
Research Site, Beijing, 102218 China
Research Site, Changde, 415000 China
Research Site, Changsha, 410015 China
Research Site, Changzhou, 213000 China
Research Site, Chengdu, 611130 China
Research Site, Hefei, 230601 China
Research Site, Huangshi, 435000 China
Eligibility Criteria
Inclusion Criteria: * Adult participant aged 18 years or older at the time of informed consent. * Body mass index (BMI) at screening of: * 28 kg/m\^2 or higher, or * 24 kg/m\^2 to less than 28 kg/m\^2 with at least 1 weight-related comorbidity. * Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change) * History of at least 1 self-reported unsuccessful dietary effort to lose body weight. * Participants with type 2 diabetes mellitus, if enrolled, and have HbA1c from 6.5% to less than 10.0% at screening. Exclusion Criteria: * Any of the following medical history, laboratory values, or complications related to diabetes: * T1DM * HbA1c ≥ 10% (86 mmol/mol) at the screening visit * Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema. * Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms. * History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis. * History/family history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2.
Conditions Diabetes Mellitus Type 2
Phase NA
Enrollment 40
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This randomized, triple-blind clinical trial investigates whether adding truncal vagotomy to Roux-en-Y gastric bypass (RYGB) enhances remission of type 2 diabetes mellitus (T2DM) in patients with obesity. The study explores whether modulation of vagal signaling provides superior metabolic outcomes compared to standard RYGB alone. Background: RYGB is a proven metabolic procedure capable of inducing diabetes remission; however, the mechanisms remain incompletely defined. Emerging evidence supports a duodenum-centered neurohormonal model suggesting that amplified digestion-driven by vagal and hormonal hyperstimulation-plays a key role in the development of insulin resistance. The vagus nerve regulates pancreatic and biliary secretion, as well as gut hormone release. By combining truncal vagotomy with RYGB, the study aims to attenuate vagal overactivation and evaluate its impact on glucose homeostasis and hormonal adaptation. Design: Eligible adults (18-65 years) with BMI ≥30 kg/m² and confirmed T2DM (HbA1c ≥6.5%, or on antidiabetic therapy with HbA1c ≥6.1%) will be randomized to: 1. RYGB alone, or 2. RYGB with truncal vagotomy. Participants, postoperative staff, and assessors will remain blinded to allocation. Primary Outcome: Remission of T2DM at 12 months postoperatively, defined as fasting plasma glucose \<100 mg/dL and HbA1c \<6.0% without antidiabetic medication for at least one year. Secondary Outcomes: Changes in HbA1c, fasting glucose, insulin, C-peptide, OGTT-derived indices, GLP-1, CCK, PYY, GLP-2, oxyntomodulin responses, HOMA-IR, body composition, cardiovascular risk markers, medication use, and quality-of-life parameters. Surgical metrics include hospital stay, readmissions, complications, gastrointestinal symptoms, nutritional deficiencies, and bone density changes. Follow-Up: Assessments occur preoperatively and at 1, 3, 6, and 12 months after surgery. Significance: The VagusSx Trial tests whether targeted vagal and duodenal pathway interruption can improve glycemic control beyond weight loss alone, offering a novel, physiology-based strategy for durable diabetes remission.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Procedure: Roux-en-Y Gastric Bypass plus Truncal Vagotomy — Laparoscopic Roux-en-Y gastric bypass performed according to protocol, including creation of a small gastric pouch, gastrojejunostomy, and jejunojejunostomy. In addition, bilateral truncal vagotomy is performed at the distal esophagus, dividing both anterior and posterior vagal trunks to reduce vagal stimulation of the gastrointestinal tract. The combined procedure aims to assess whether vagotomy enhances type 2 diabetes mellitus remission beyond the effect of gastric bypass alone.
  • Procedure: Roux-en-Y Gastric Bypass — Laparoscopic Roux-en-Y gastric bypass performed according to protocol, including creation of a small gastric pouch, gastrojejunostomy, and jejunojejunostomy. No vagotomy is performed. This serves as the active comparator to evaluate the independent effect of adding truncal vagotomy on type 2 diabetes mellitus remission.

Primary Outcomes

  • Complete remission of Type 2 Diabetes Mellitus at 12 Months Post-Surgery (12 months postoperatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-24
Completion: 2028-12
Eligibility
Age: 18 Years – 68 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Research Institute for the Study of Genetic & Malignant Disorders in Childhood
Collaborators: National and Kapodistrian University of Athens
Contact Information
Study Contact:
Athena N Kapralou, MD, PhD
+306945750599
athinakapralou@gmail.com
Athena N Kapralou, MD, PhD
+306945750599
athinakapralou@gmail.com
Diabetes Surgery
Athena Kapralou, MD, PhD
+30 6945750599
athinakapralou@gmail.com
Diabetes Surgery
Interventions
  • Procedure: Roux-en-Y Gastric Bypass plus Truncal Vagotomy — Laparoscopic Roux-en-Y gastric bypass performed according to protocol, including creation of a small gastric pouch, gastrojejunostomy, and jejunojejunostomy. In addition, bilateral truncal vagotomy is performed at the distal esophagus, dividing both anterior and posterior vagal trunks to reduce vagal stimulation of the gastrointestinal tract. The combined procedure aims to assess whether vagotomy enhances type 2 diabetes mellitus remission beyond the effect of gastric bypass alone.
  • Procedure: Roux-en-Y Gastric Bypass — Laparoscopic Roux-en-Y gastric bypass performed according to protocol, including creation of a small gastric pouch, gastrojejunostomy, and jejunojejunostomy. No vagotomy is performed. This serves as the active comparator to evaluate the independent effect of adding truncal vagotomy on type 2 diabetes mellitus remission.
Study Locations (2 sites)
Diabetes Surgery, Athens, Attica 11527 Greece
Diabetes Surgery, Athens, Attica 11527 Greece
Eligibility Criteria
Inclusion Criteria: * BMI ≥ 30 kg/m² * Age: 18-68 years * Confirmed type 2 diabetes mellitus with: * HbA1c ≥ 6.5%, or * HbA1c ≥ 6.1% and the use of antidiabetic medication * Advanced-DiaRem Score \> 5\* \* Advanced-DiaRem Score: a validated scoring system predicting diabetes remission after bariatric surgery. Exclusion Criteria: * Previous bariatric surgery or major abdominal surgery (e.g., enterectomy, gastrectomy, colectomy, hepatectomy, partial or total pancreatectomy) * Major, uncompensated health problems (major psychiatric, endocrine, cardiac, pulmonary, hepatic, or renal disorder; cancer; or other conditions with increased risk of complications) * Use of corticosteroids (glucocorticoids): * Chronic corticosteroid use for \> 3 months within the last year, or * Corticosteroid therapy within the last 3 months * Type 1 diabetes mellitus * Alcohol or drug addiction
Conditions Metabolic Dysfunction-Associated Steatot...
Phase Not Applicable
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

LiverSeek is a fully automated, passive case-finding programme for advanced liver fibrosis associated with metabolic dysfunction-associated steatotic liver disease (MASLD) in primary care. The programme operates through the Laboratory Information System (LIS; Modulab/Biwer Analytics) of the Clinical Biochemistry Laboratory at Hospital General Universitario Gregorio Marañón (HGUGM), covering approximately 350,000 inhabitants across 11 peri-urban primary care centres affiliated to SERMAS (Servicio Madrileño de Salud) in Madrid, Spain. When a high-risk patient (age 50-75 years with ≥1 of: ALT above ULN + HbA1c ≥6.5%; ALT above ULN + BMI \>30; BMI \>30 + HbA1c ≥6.5%) undergoes a routine blood test in primary care, the LIS automatically calculates FIB-4. If FIB-4 \>1.30, the system reflexively orders ELF and MASEF from the same serum sample, without any action required from the primary care clinician. Patients with a positive second-step NIT (ELF ≥9.8 or MASEF ≥0.33) receive an automatic alert directing them to the Hepatology Advanced Practice Nurse for VCTE (FibroScan) and clinical evaluation. The primary objective is to evaluate the prevalence of hepatic fibrosis in the high-risk population using this single-step automated strategy. Secondary objectives include head-to-head diagnostic comparison of FIB-4+ELF vs FIB-4+MASEF vs FIB-4+FAST for histologically-confirmed endpoints (significant fibrosis ≥F2, advanced fibrosis ≥F3, at-risk MASH), evaluation of the Liver Risk Score, and a health-economic analysis. A sub-study evaluates a nurse-led structured lifestyle intervention in NIT-positive patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of hepatic fibrosis detected by the automated single-step case-finding strategy (Within 3 months of index blood test)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-01
Completion: 2027-09-01
Eligibility
Age: 50 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hospital General Universitario Gregorio Marañon
Collaborators: Instituto de Investigación Sanitaria Gregorio Marañón, Consorcio Centro de Investigación Biomédica en Red (CIBER)
Principal Investigators:
  • Rafael Bañares, Full-Professor of Medicine (STUDY_CHAIR) - Universidad Complutense de Madrid, President of Spanish Association for the Study of the Liver (AEEH)
  • Magdalena Salcedo, MD, PhD (STUDY_CHAIR) - President of the Spanish Society of Liver Transplantation (SETH)
Contact Information
Study Contact:
Luis Ibáñez-Samaniego, MD, PhD
+34 91 586 8308
luis.ibanez@salud.madrid.org
Luis Ibáñez-Samaniego, MD, PhD
+34 91 586 8308
luis.ibanez@salud.madrid.org
Hospital General Universitario Gregorio Marañón
Susana Sanchez Berdial, Pharm
ssberdial@salud.madrid.org
Hospital General Universitario Gregorio Marañón
Interventions
N/A
Study Locations (1 sites)
Hospital General Universitario Gregorio Marañón, Madrid, Madrid 28007 Spain
Eligibility Criteria
Inclusion Criteria: 1. Age between 50 and 75 years (inclusive) 2. Routine blood test processed in the Clinical Biochemistry Laboratory of Hospital General Universitario Gregorio Marañón, ordered by a primary care physician in one of the 11 affiliated SERMAS primary care centres 3. Presence of at least one of the following metabolic risk factor combinations: * ALT above the upper limit of normal AND HbA1c ≥6.5% * ALT above the upper limit of normal AND BMI \>30 kg/m² * BMI \>30 kg/m² AND HbA1c ≥6.5% Exclusion Criteria: 1. Age \<50 years or \>75 years 2. Known pre-existing liver disease (significant or advanced fibrosis, cirrhosis, hepatocellular carcinoma, prior liver transplantation) 3. Prior fibrosis assessment within the preceding 12 months.
Conditions Diabetic Foot Ulcer (DFU), Chronic Foot ...
Phase NA
Enrollment 240
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this clinical investigation is to evaluate the safety and efficacy of Amnion/Chorion/Amnion allograft , Amnion/Chorion allograft, and/or Amnion/Amnion allograft, plus Standard of Care (SOC) each versus SOC alone in the treatment of chronic non-healing diabetic foot ulcers (DFU) after 12 weeks of treatment.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Allograft — Placental-based Allografts

Primary Outcomes

  • Percentage of DFUs healed at 12 weeks (12 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-14
Completion: 2026-11-18
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tides Medical
Collaborators: Professional Education and Research Institute
Principal Investigators:
  • David G Armstrong, DPM, MD, PhD (STUDY_CHAIR) - Keck School of Medicine of USC
  • Frank Burrows, MBA, EMT, BCMAS, CWCA (STUDY_DIRECTOR) - Tides Medical
Contact Information
Study Contact:
Frank Burrows III, MBA, EMT, BCMAS, CWCA
888-494-4441
FBurrows@tidesmedical.com
Mora Melican, PH.D.
888-494-4441
MMelican@tidesmedical.com
Destiny Blackstone
559-431-1700
destiny@lppresearch.com
Limb Preservation Platform Inc
Interventions
  • Other: Allograft — Placental-based Allografts
Study Locations (9 sites)
Limb Preservation Platform Inc, Fresno, California 93710 United States
Angel City Research, Los Angeles, California 90010 United States
Clemente Clinical Research, Los Angeles, California 90033 United States
ILD Research Center, Vista, California 92081 United States
Clever Medical Research, Miami, Florida 33126 United States
Foot and Ankle Specialists of the Mid-Atlantic, Raleigh, North Carolina 27609 United States
Lower Extremity Institute of Research and Therapy, Boardman, Ohio 44512 United States
Brock Liden DPM, Circleville, Ohio 43113 United States
Foot and Ankle Specialists of the Mid-Atlantic, Salem, Virginia 24153 United States
Eligibility Criteria
Inclusion Criteria: Potential subjects are required to meet all of the following criteria for enrollment into the study. 1. At least 18 years old, inclusive. 2. Presence of a DFU, Wagner Grade 1, extending through the dermis provided it is below the medial aspect of the malleolus. 3. The index ulcer (ulcer to be evaluated in the study) will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer. 4. Index ulcer has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study. 5. Index ulcer is a minimum of 1.0 cm2 and a maximum of 25 cm2 at SV1 and TV1. 6. Within 3 months of SV1, adequate circulation to the affected foot as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 using the affected study extremity. As an alternative, arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of \> 0.6 is acceptable. 7. The target ulcer has been offloaded for at least 14 days, prior to TV1. 8. Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests. 9. Subject understands and is willing to participate in the clinical study and can comply with weekly visits. 10. Subjects must have read and signed the IRB approved ICF before screening procedures are performed. Exclusion Criteria: Potential subjects meeting any of the following criteria will be excluded from enrollment and subsequent treatment. 1. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes 2. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer 3. Index ulcer is infected 4. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study 5. Subjects on any investigational drug(s), Investigational products, or therapeutic device(s) within 30 days preceding SV1 6. History of radiation at the ulcer site (regardless of time since last radiation treatment) 7. Index ulcer has been previously treated or will need to be treated with any prohibited therapies 8. Subjects with a previous diagnosis of HIV or Hepatitis C 9. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment 10. Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision) 11. Subject is pregnant or breast-feeding 12. Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 within last 90 days 13. Subjects with end stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of enrollment 14. Presence of acute Charcot Neuroarthropathy to the affected limb 15. Index ulcer that has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit